1. Introduction {#s0005}
===============

There has been a growing concern over functional outcome in patients with schizophrenia ([@bb0015]) since its inclusion in DSM-III or later editions. Functional outcome refers to a wide range of real-world functioning including residential independence, employment, daily-living skills (e.g. financial management, telephone communication), or social activities ([@bb0040]). The role of cognitive deficits in impaired functional outcome has been well-conceptualized with the advent of the Measurement and Treatment Research to Improve in Schizophrenia Consensus Cognitive Battery ([@bb0130], [@bb0135]). Although the initial purpose of the MCCB was to provide a comprehensive battery sensitive to neurocognitive improvement by drug treatment, co-primary measures, predictive of real-world functioning, were also requested to accommodate the development of cognitive enhancers ([@bb0010]).

Performance-based batteries such as the UCSD Performance-based Skills Assessment-Brief ([@bb0115]) have been shown to provide a potential co-primary measure, satisfying 1) test--retest reliability, 2) a moderate practice effect, 3) a high completion rate, 4) a good correlation with neurocognitive performance, and 5) a discriminability for residential status and social involvement, such as work ([@bb0095], [@bb0100], [@bb0115], [@bb0110], [@bb0105], [@bb0140]).

As the name suggests, tasks in the UPSA-B are role-played using props (e.g. money, an invoice, a letter, and a telephone etc.) to evaluate functional capacity (competence) in daily-living contexts ([@bb0115], [@bb0105]). The battery consists of two subscales: Finances (e.g. counting money, bill payment) and Communication (e.g. using a phone). They were extracted from the full version of the original UPSA ([@bb0150]) based on factor analysis ([@bb0115]). Due to its conciseness (approximately 10--15 min) and effectiveness as a co-primary measure, the battery has been widely used in the US, and has been introduced in Europe (Sweden: [@bb0045], [@bb0140], [@bb0175]; Denmark: [@bb0175]) and Asia (China: [@bb0125]; India: [@bb0165]) ([Table 1](#t0005){ref-type="table"}). Also, the Japanese version ([@bb0160]) is under standardization.Table 1The UPSA-B studies in the US and other countries.CountryStudyParticipants[a](#tf0005){ref-type="table-fn"}NUPSA-B[b](#tf0010){ref-type="table-fn"}Sample[c](#tf0015){ref-type="table-fn"}TotalFinancesCommunicationUS[@bb0005]SCZ16169.9----Patients with schizophrenia or schizoaffective disorder who were community living with Ashkenazi Jewish backgrounds. Results were obtained from the analyses of subsamplesBD13088.5[@bb0035]SCZ16273.0----Recruited at the Validation of Intermediate Measure (VIM) study under the MATRICS initiative[@bb0065]SCZ344574.0----Enrolled in the genomic study based on a Veterans Administration initiative (CSP\#572)BD462483.0[@bb0085]SCZ32370.0----Participants were in a large multi-site trial assessing the comparative effects of antipsychotic treatment with lurasidone or risperidone[@bb0095]SCZ19472.2----Older patients with schizophrenia enrolled in longitudinal study of the course of cognitive and functional status. They were recruited at Mt. Sinai School of Medicine or other hospitals[@bb0100]SCZ (Mt. Sinai)23868.7[d](#tf0020){ref-type="table-fn"}----Part of data was from [@bb0095]SCZ (UCSD)11656.5Recruited from Board and Care facilities in San Diego who enrolled in Functional Adaptation Skills TrainingNC10984.5Healthy subjects recruited at a naturally occurring retirement community (NORC) in Manhattan[@bb0115]Independent living SCZ9972.5----Recruited at the UCSD Advanced Center for Interventions and Services Research. A subset of participants was part of the Functional Adaption Skills Training (FAST) study ([@bb0155])Non-independent living SCZ33554.5[@bb0110]Assisted-living, SCZ, Schizoaffective16353.9----Part of data was from the FAST studyCommunity-living SCZ, Schizoaffective7354.7China[@bb0125]SCZ (Chinese)27237.6----Inpatients treated at a municipal psychiatric hospital in BeijingBD (Chinese)6155.2Major depression (Chinese)5047.9NC (Chinese)28464.3India[@bb0165]SCZ (Indian)16067.6----Recruited from 6 different sites recommended by the MATRICS Scientific Advisory BoardUS[@bb0055]SCZ (Atlanta Skyland Trail)5575.5Enrolled in the Validation of Everyday Real-World Outcomes (VALERO) study ([@bb0055], [@bb0070])SCZ (Atlanta VA Medical Center)4081.740.1--[@bb0070]SCZ (UCSD Outpatients Psychiatric Services)10075.3[@bb0020]SCZ, Schizoaffective18340.036.4Data from the three different services referred in the VALERO study ([@bb0055], [@bb0070])[@bb0050]SCZ, Schizoaffective23668.8----Schizophrenia or schizoaffective participants in a longitudinal study of cognitive and functional status. Outpatients recruited from several sites in New York and its suburbs[@bb0045]SCZ24437.431.5Data from the same general data set in [@bb0045], [@bb0050][@bb0120]SCZ11675.639.536.1Data from the same resource in [@bb0005]BD8988.745.743.0[@bb0105]SCZ36777.541.136.4Sweden[@bb0045]SCZ (Swedish)14668.938.730.9Outpatients recruited at a country council-founded clinic at NU Health Care Hospital[@bb0140]SCZ, Schizoaffective, Delusional (Swedish)21169.438.830.6Participants were in the study of Clinical Long-term Investigation of Psychosis in Sweden (CLIPS)Denmark[@bb0175]First episode SCZ (Danish)11777.540.237.3Participants were in the multi-site randomized clinical trial for cognitive remediation program (the NEUROCOM trial)[^1][^2][^3][^4]

Although the UPSA-B has promise for assessing functional capacity, some issues remain under consideration in developing its Japanese version. First, the normative performance on the Japanese version needs to be clarified. To date, several studies have presented data of a normal population ([@bb0100], [@bb0125]). According to these reports, the achievement of the normal samples ranges from 60 to 85 ([Table 1](#t0005){ref-type="table"}), which may be affected by age and educational attainment. The study with the US samples ([@bb0100]) presented scores of elderly healthy people (the mean age = 68.0) with large effect sizes between schizophrenia patients (*d* = 0.90--1.58 across multiple sites). On the other hand, Chinese control subjects who had relatively low levels of average educational attainment (Mean = 8 years) elicited a considerably lower score (64.3) ([@bb0125]), while the disassociation from normal controls (*d* = 1.08) was the same degree as that in the US study ([@bb0100]).

The normative performance differentiating between normal and clinical samples can also be discussed from the view point of independency of living. The initial development study of the UPSA-B ([@bb0115]), examined a cut-off point classifying patients with schizophrenia into independent- versus non-independent living groups. A score of around 60 was estimated as the optimal cut-off, suggesting that patients above that have the capacity to live independently as a part of the normal population. Given the rather wide range of scores of the achievement related to the standard, an optimal cut-off point, differentiating normal subjects from patients, needs to be determined for the Japanese version of the UPSA-B. Specifically, data from relatively younger (30--50 years old) normal samples are of concern, which has not been addressed in previous studies.

Second, the possible influence of the cultural or socio-economical backgrounds needs to be considered. Cross-cultural adaptability of functional outcome measures including the UPSA-B has been discussed among its developers ([@bb0030], [@bb0075], [@bb0170]). Ratings by experts in different countries including Europe, Russia, and Asia resulted in a relatively poorer cultural adaptability of the UPSA-B compared to the case in the US, due probably, to the difference in daily-living standards. Specifically, Mexico, India, and China presented the greatest challenges in adaptation ([@bb0170]). On the other hand, the UPSA-B may be well accommodated in countries with relatively uniformly westernized living environments like Japan.

Third, the Japanese version of the UPSA-B is expected to serve as an effective co-primary measure for standard neurocognitive batteries such as the MCCB, as shown by previous studies ([@bb0035]). Accordingly, the correlation with cognitive functioning needs to be evaluated as part of the development of the UPSA-B_J.

The purposes of the current study were to address those issues in showing the utility of the UPSA-B in Japan. First, the performance on the UPSA-B was compared between young or middle-aged normal controls and patients with schizophrenia. A cut-off point differentiating normal controls from patients was also determined. In addition, profiles of the task performance were produced to see if the domain- and task-specific difficulties exist in both groups. Finally, the relation to neurocognitive functioning, as assessed by the MCCB-J, was investigated to confirm its validity as a co-primary measure.

2. Methods {#s0010}
==========

2.1. Participants {#s0025}
-----------------

Sixty-four Japanese patients with schizophrenia and 83 healthy adults entered the study. Demographic and clinical profiles of the participants are summarized in [Table 2](#t0010){ref-type="table"}. Patients were outpatients treated in Okayama University Hospital, and public or private hospitals in Toyama Prefecture. Diagnosis was established based on the DSM-IV-TR criteria by experienced psychiatrists using a structured interview, reference to medical history, and all available information. Patients known to be abusing alcohol or illicit drugs, or those with epilepsy, brain damage, or neurologic disorders, were excluded from the study. Psychiatric symptoms were assessed on the Brief Psychiatric Rating Scale (BPRS), 18-item version ([@bb0145]).Table 2Characteristics of participants.NCSCZEffect size[a](#tf0025){ref-type="table-fn"}t/F (df)pInterpretationsN (M/F)83 (71/12)64 (34/30)--Age34.6 (9.4)[b](#tf0030){ref-type="table-fn"}35.2 (11.2)--t = − 0.13 (143)0.72NC = SCZEducation16.6 (1.1)13.6 (2.4)--t = 10.12 (143)\< 0.000NC \> SCZDuration--9.7 (8.1)----Drug (mg)[c](#tf0035){ref-type="table-fn"}--444.8 (492.0)----BPRS_Positive--10.0 (5.9)----BPRS_Negative--7.5 (3.4)----BPRS_Total--36.5 (12.8)----MCCB Composite510.5 (47.3)376.3 (76.0)2.1F = 67.30 (1,140)\< 0.000NC \> SCZUPSA-B Total82.1 (8.6)69.5 (13.7)1.1t = 6.80 (145)\< 0.000NC \> SCZ Finances48.7 (3.3)43.8 (7.8)0.8F = 46.24 (1,145)\< 0.000NC \> SCZ Communication33.4 (7.6)25.7 (9.5)0.9[^5][^6][^7][^8]

Normal controls were recruited at Okayama University. The majority of them were office employees working in Okayama Prefecture. Written informed consent was obtained from all participants. The study protocol was approved by ethics committees at the respective study sites.

2.2. Measures {#s0030}
-------------

The Japanese versions of UPSA ([@bb0160]) and MCCB were administered to all participants. The UPSA-B Japanese version was developed based on the international version of the UPSA-B, with some modifications to adjust for differences in everyday functional demands in Japan. It has been approved by developers after conducting two independent forward and back translations, reconciliation, and pilot testing on patients. The MCCB Japanese version has been shown to have good psychometric properties and validity ([@bb0080]).

Subscale scores of the two domains of the UPSA-B (i.e. Finances, Communication) were converted into the standard score ranging from 0 to 50, and thus the maximum of the Total score was 100 ([@bb0115]). Raw scores for the 10 subtests of the MCCB were converted to *T*-scores (mean = 50, SD = 10), out of which the seven domain scores were produced ([@bb0130]). The *T*-score of each task corresponds to the domain score except for Speed of Processing (TMT, BACS SC, and Fluency) and Working Memory (LNS and WMS-SS), for which the composite scores were calculated by summing to the *T*-scores of tests included in those domains. The overall composite score was the sum of the seven domain scores ([@bb0090], [@bb0130]).

The formal Japanese version of the MCCB was not released at that moment, and thus, the *T*-scores of the Japanese version were produced based on the data obtained in a preliminary study for the development of the Japanese version; the normative group consisted of 85 healthy adults (mean age = 40.0, SD = 11.2, range 19--65) and the mean and the standard deviation of this group served as the reference for the *T*-score conversion. Age-correction was applied according to the regression method employed in the standardization study in the US ([@bb0090]). Although both age- and gender-corrections are recommended in the MCCB Manual ([@bb0130]), only the former was applied due to limitations in the reference group at that moment.

2.3. Statistical analyses {#s0035}
-------------------------

SPSS ver. 17.0 (SPSS Inc.) was used for all the analyses except for the estimation of effect sizes.

2.4. Group comparisons {#s0040}
----------------------

Demographic variables (age and education) and the UPSA-B Total score were compared by *t*-test. Two-way analysis of variance (Two-way ANOVA) was conducted for the group comparisons for the UPSA-B subscales with Group (normal controls vs. patients) as a between-subject factor while Subscale (Finances vs. Communication) as a within-subject factor. The MCCB composite score was compared by one-way analysis of covariance (ANCOVA) controlling education. Effect sizes (Cohen's *d*) were calculated by dividing the mean difference between normal controls and patients by a pooled SDs from the two groups.

2.5. ROC curve analyses {#s0045}
-----------------------

Receiver Operating Characteristic (ROC) curves analyses were conducted for the UPSA-B Total and subscale scores. Every possible cut-off point was specified at a specific sensitivity and 1 − specificity. Sensitivity corresponds to the 'hit' rate indicating the correct classification of normal subjects as a normal sample. 1 − specificity and specificity represent the 'false alarm (FA)' and 'correct rejection (CR)' rates, respectively. The former refers to the rate of misclassifying patients into the normal sample, while the latter means the rate of correctly determining patients. As for the measure of sensitivity, the area under curve (AUC) with the 95% confidential interval (95% CI) and *d*ʹ (*d*-prime) ([@bb0025]) were calculated; larger values suggest better sensitivity. Optimal cut-off points were determined for the UPSA-B Total score, at which the sum of sensitivity (% of hit) and specificity (% of CR) was maximized (Youden\'s *J*: [@bb0180]); ([@bb0105]).

2.6. Profiles for the UPSA-B {#s0050}
----------------------------

Profiles were created to show domain- or task-specific performance in each group. The mean scores were calculated for each task (MAX = 1 except for one task with MAX = 2 in the Finance part), and were plotted on a horizontal axis scaled with task numbers.

2.7. Correlation analyses {#s0055}
-------------------------

Simple correlations (Pearson's *r*) were calculated between the UPSA-B Total score and the MCCB overall composite and seven domain scores.

3. Results {#s0015}
==========

3.1. Group comparisons {#s0060}
----------------------

[Table 2](#t0010){ref-type="table"} presents the statistical results for demographic variables and the performance on the UPSA-B and the MCCB. Age did not differ between groups (*t* = − 0.36, *df* = 143, *n.s.*) while Education was significantly higher for normal controls (*t* = 10.12, *df* = 143, *p* \< 0.01). The UPSA-B Total score (*t* = 6.80, *df* = 145, *p* \< 0.01) and the MCCB composite score (*F* = 67.30, *df* = 1, 140, *p* \< 0.01) were significantly higher for normal controls than Main effects of Group and Subscales of the UPSA-B were significant without an interaction effect; normal controls performed better than patients (*F* = 46.24, *df* = 1, 145, *p* \< 0.01) on both Finances and Communication subscales, and the Finances score was higher than Communication in both groups (*F* = 474.18, *df* = 1, 145, *p* \< 0.01).

Overall, relatively large ESs were obtained (*d* ≥ 0.8), suggesting that substantial differences existed between normal controls and patients in measures of both functional capacity (UPSA-B) and neurocognition (MCCB) ([Table 2](#t0010){ref-type="table"}).

3.2. ROC curve analyses {#s0065}
-----------------------

[Fig. 1](#f0010){ref-type="fig"} illustrates ROC curves for the UPSA-B Total score. AUC of 0.77 (95%CI: 0.70--0.85) was significantly greater (*p* \< 0.001) than that of no information (0.50). *dʹ* associated with this curve was estimated as 1.26.Fig. 1ROC curves for UPSA-B Total score.

The optimal cut-off point for the Total score (MAX = 100) was estimated as 77.8, at which sensitivity (hit rate) and 1 − specificity (FA rate) were 0.67 and 0.21, respectively. The results suggest that of all normal controls, 67% had the UPSA Total score of 77.8 or above, while of all patients, 89 (= 100 − 21)% scored below this score.

3.3. Profiles of the UPSA-B {#s0070}
---------------------------

[Fig. 2](#f0005){ref-type="fig"} presents profiles of UPSA-B scores for normal controls (A) and patients with schizophrenia (B). Normal controls performed almost perfectly on the Finances part ([Fig. 2](#f0005){ref-type="fig"}A, the left section). Likewise, the patient group showed better performance on the Finances part ([Fig. 2](#f0005){ref-type="fig"}B, the left section) than the Communication part ([Fig. 2](#f0005){ref-type="fig"}B, the right part).Fig. 2UPSA-B profiles for normal controls (A) and patients with schizophrenia (B). Task 13: Speaking to the phone a name and an address given by a tester. Task 16: Leaving a voice-mail message to a reschedule of an appointment. Task 19: Remembering preparations designated by a medical appointment.

Both normal controls and patients tended to perform poorly on Task 13 (speaking on the phone with a name and an address given by the tester), Task 16 (leaving a voice-mail message to reschedule an appointment), and Task 19 (remembering preparations designated by a medical appointment) ([Fig. 2](#f0005){ref-type="fig"} A, B).

3.4. Correlations between the UPSA-B and the MCCB {#s0075}
-------------------------------------------------

Correlations between the MCCB measures and the UPSA-B Total score scores were presented in [Table 3](#t0015){ref-type="table"}. On the whole, the patient group yielded relatively larger *r*s than the normal control group ([Table 3](#t0015){ref-type="table"}). The MCCB Overall composite, Working Memory composite, and Verbal Learning in the patient group showed moderate correlations (≥ 0.3) reaching a statistical significance. Attention/Vigilance was also significantly correlated with the UPSA-B Total score. in both groups, although the *r*s were modest (0.23--0.27). The MSCEIT had the weakest relationship to the UPSA-B Total score, not revealing substantial correlations (≤ 0.1) in either group ([Table 3](#t0015){ref-type="table"}).Table 3Correlations between the MCCB and the UPSA-B.MCCB domains and testsNCSCZOverall composite[a](#tf0050){ref-type="table-fn"}0.27[\*](#tf0040){ref-type="table-fn"}0.35[\*\*](#tf0045){ref-type="table-fn"}Speed of Processing Composite[b](#tf0055){ref-type="table-fn"}0.150.25 Trail Making Test BACS Symbol Coding FluencyWorking Memory Composite[c](#tf0060){ref-type="table-fn"}0.210.36[\*\*](#tf0045){ref-type="table-fn"} WMS-II Spatial Span Letter Number SequencingVerbal Learning0.060.36[\*\*](#tf0045){ref-type="table-fn"} HVLT-RReasoning and Problem solving− 0.010.20 NAB MazeVisual Learning0.190.24 BVMT-RSocial Cognition0.16− 0.10 MSCEIT Managing EmotionAttention/Vigilance0.23[\*](#tf0040){ref-type="table-fn"}0.27[\*](#tf0040){ref-type="table-fn"} CPT-IP[^9][^10][^11][^12][^13][^14]

4. Discussion {#s0020}
=============

The principal findings of the current study are summarized as follows: (1) the Japanese version of the UPSA-B has good discriminating power for diagnostically different groups yielding a large effect size (*d* ≥ 0.8) and optimal cut-off point (around 80), (2) the Finance subscale of the UPSA-B was markedly better performed than the Communication subscale in both healthy adults and patients, showing poor performances on certain tasks in the Communication subscale, and (3) Performance on the UPSA-B Japanese version reflected neurocognitive functioning especially in patients with schizophrenia.

The average score of the UPSA-B Total score of the normal sample obtained in the current study was above 80, consistent with [@bb0100]. Given that a majority of the studies from the US and Europe have reported that the averages of patients fell under 80 ([Table 1](#t0005){ref-type="table"}), and that the optimal cut-off point in the current study was 78.8, it seems to be feasible to set the discriminative point at around 80 (less than 3--4 failures out of 20 tasks). In other words, the point around here is suggested to be an endpoint for patients with schizophrenia to live and function well in the community.

The disassociation between patients and normal controls found here was also in accord with a study in China ([@bb0125]), yielding relatively larger effect sizes (*d* ≥ 0.8). Although the scores of Chinese samples were lower than other studies ([Table 1](#t0005){ref-type="table"}), this is due to a wide range of educational attainment in the research participants who were selected, in order to show that the UPSA-B was sensitive to education and that patients with low levels of education would have poor performance because of both educational and illness related variables ([@bb0125]).

In addition to the diagnostically critical point noted above, identification of 'functional milestones' (e.g. goal lines for achievement in residential independence or employment) ([@bb0105]) would be informative for patients undergoing their rehabilitation. Previous studies exploring those cut-offs have reported that a score of 60 or above was able to be used to determine independent- vs. assisted-living status ([@bb0115]), and a score of 80 or above was able to be used to predict employment status (≥ 20 h/week) ([@bb0105]). It would be of importance to investigate whether a similar degree of achievement is required for those functional milestones in westernized Asian countries like Japan.

As was suggested by the average score of subscales ([Table 2](#t0010){ref-type="table"}) and the profile analyses ([Fig. 2](#f0005){ref-type="fig"}), the performance on the UPSA-B may vary depending on the domains; ANOVA results indicated that the Finances subscale was considerably higher than that of the Communication subscale in both the normal and the patient groups. In fact, our normal controls nearly gained the maximum score of 50, suggesting that healthy adults are expected to be almost perfect in this domain. Previous studies have also reported that the average of the Finances domain exceeded 40 even in people with schizophrenia ([@bb0020], [@bb0115], [@bb0175]) ([Table 1](#t0005){ref-type="table"}). Given these discrepant figures between the subscales, the Total score on the UPSA-B is preferable for the purposes of general classification of functioning on the part of people with schizophrenia. Also, our supplementary analyses showed that discriminative ability of single subscales alone (Finances: AUC = 0.68, *d*ʹ = 1.0; Communication: AUC = 0.73, *d*ʹ = 1.3) was poorer than that of theTotal score (AUC = 0.77, *d*ʹ = 1.3).

The profile analysis showed similar trends between normal controls and patients for the Communication subscale. Both groups presented a relatively low score at memory-demanding tasks (Tasks 13, 16, and 19; [Fig. 2](#f0005){ref-type="fig"}). Our preliminary analysis including university students (*N* = 30, mean age = 20.6) performed well on those tasks, suggesting that age- and/or disease-based degradation of memory may account for poor performance.

The UPSA-B Total score showed a significant and moderately good correlation with the MCCB Composite score in patients with schizophrenia (*r* ≥ 30), indicating sensitivity of the Japanese version of the UPSA-B to overall cognitive functioning in a clinical population. Moreover, in the patient group, Working memory and Verbal learning, in particular, showed relatively larger correlations compared to other domains, consistent with a previous report by [@bb0020]. Interestingly, the MSCEIT was excluded from the MCCB composite score in their study, assuming that social cognition would substantially differ from neurocognition in terms of the relationship to everyday functioning. Our result seems to support their assumption, as revealed by the weakest correlations between the MSCEIT and the UPSA-B measure in both normal controls and patients ([Table 3](#t0015){ref-type="table"}).

Several issues are worth discussing in order to enhance the utility of the UPSA-B Japanese version. First, essential psychometric properties, including test--retest reliability, practice effect, and potential sensitivity in response to treatment need to be examined. Although previous studies ([@bb0100], [@bb0165]) have reported the UPSA-B has good qualities in these aspects, these issues should be replicated with the Japanese version of the UPSA-B.

Second, stratified cut-off points according to types of functional recovery (e.g. residential status, employment) ([@bb0105]) or demographic variables (e.g. age) would be worth investigating. Regarding the latter, as noted before, healthy adults have been shown to perform well (≥ 80) on the UPSA-B ([@bb0100]). Similarly, a study with the full version of the UPSA ([@bb0060]) has reported that basic daily-living activities were relatively unaffected by age, based on data from healthy elderly population. Despite those facts, our preliminary data indicate that younger subjects (university students) performed better than middle-aged workers for the Communication subscale (students = 38.5, workers = 33.4). This suggests that the execution of this battery might be age-dependent to a certain degree. Besides, the normal achievement might become less demanding as a person gets older; elderly people may not be expected to be as equally efficient as younger people who are generally more productive in work or social activities. Whether the performance on the UPSA-B is affected by age or socio-economical requirements warrants further investigations. Results from such studies may indicate a need for stratified standard scores or cut-offs.

Finally, as noted in a previous study ([@bb0175]), updated versions with or without supplemental tasks/props would facilitate the application to subjects with a wide range of demographic backgrounds.

To conclude, our study has presented data which confirmed the utility of the Japanese version of the UPSA-B. The battery has a good discriminative validity in differentiating patients with schizophrenia from a healthy middle-aged population, consistent with previous studies using elderly samples. Further, the responsiveness to cognitive functioning in patients with schizophrenia adds support to the utility of the UPSA-B as a co-primary measure in westernized countries like Japan.
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[^1]: SCZ: schizophrenia, BD: bipolar disorder, NC: normal controls.

[^2]: MAX score: Total = 100, Finances = 50, Communication = 50.

[^3]: Patients were mostly outpatients except for [@bb0125].

[^4]: A base line score.

[^5]: NC: normal controls, SCZ: patients with schizophrenia.

[^6]: Cohen\'s *d* for normal controls vs. patients.

[^7]: Mean (SD).

[^8]: CPZ equivalent.

[^9]: NC: normal controls, SCZ: patients with schizophrenia.

[^10]: p \< 0.05.

[^11]: p \< 0.01.

[^12]: The sum of the T scores for seven domains.

[^13]: The sum of TMT, BACS SC, and Fluency.

[^14]: The sum of WMS III SS and LNS.
